Stem Cell Therapy Offers Latest Hope for Babies with Spina Bifida
A groundbreaking trial is offering a beacon of hope for families affected by spina bifida. Researchers have demonstrated that applying stem cells to the spinal cords of unborn babies during surgery is safe and shows promising signs of improving mobility and quality of life. This innovative approach, led by Dr. Diana Farmer at the University of California, Davis, could potentially revolutionize the treatment of this birth defect.
The CuRE Trial: A First-of-Its-Kind Procedure
The Cellular Therapy for In Utero Repair (CuRE) trial involved six pregnant women carrying babies diagnosed with myelomeningocele, the most severe form of spina bifida. Between 24 and 25 weeks of gestation, surgeons applied placenta-derived mesenchymal stem cells (PMSCs) directly to the exposed spinal cords of the fetuses. PMSCs, obtained from donated placentas, have previously shown promise in laboratory settings for protecting and promoting the growth of neurons.
MRI scans conducted after the babies were born confirmed a reversal of hindbrain herniation – a dangerous complication of spina bifida where brain tissue descends into the neck – in all six cases. Importantly, the stem cell therapy did not cause any adverse effects such as tumor growth, infection, or wound healing complications.
How Stem Cells are Changing the Landscape of Fetal Surgery
Spina bifida occurs when the spinal cord doesn’t close completely during pregnancy. Myelomeningocele, the most severe form, can lead to paralysis, bladder and bowel control issues, and hydrocephalus (fluid accumulation in the brain). Current treatments focus on surgical repair after birth, but this doesn’t always prevent long-term neurological damage.
Dr. Farmer believes this therapy could become the standard of care if it consistently improves children’s ability to walk. “If it makes more children able to walk who wouldn’t have then it would become their standard of care,” she stated. The success of the CuRE trial suggests that intervening in utero with stem cell therapy could significantly improve outcomes.
Beyond Spina Bifida: The Potential for Regenerative Medicine
The implications of this research extend beyond spina bifida. The success of the CuRE trial demonstrates the potential of regenerative medicine to address a range of birth defects and neurological conditions. Researchers are exploring whether similar stem cell therapies could be used to treat other conditions affecting fetal development.
Dr. Magdalena Sanz Cortes, a fetal medicine expert not involved in the trial, noted that if further studies confirm these benefits, it “would herald a new era in fetal surgery and potentially lead the way to improving and reversing the neurological damage seen in utero in spina bifida.”
What Which means for Families
Currently, an estimated 536 pregnancies a year in England and Wales are affected by spina bifida, with between 8,100 and 11,900 people living with the condition. For families facing a diagnosis of myelomeningocele, this research offers a renewed sense of hope. The potential for improved mobility and quality of life is a significant step forward.
Kate Steele, CEO of the charity Shine, described the results as “very exciting,” highlighting the remarkable advances in stem cell science that made the trial possible.
Frequently Asked Questions
What is spina bifida? Spina bifida is a birth defect that occurs when the spinal cord doesn’t close completely during pregnancy.
What is myelomeningocele? Myelomeningocele is the most severe form of spina bifida, often resulting in paralysis and other neurological complications.
Where did the stem cells come from? The stem cells used in the CuRE trial were derived from donated placentas.
Is this treatment widely available? The CuRE trial was a small, initial study. Further research is needed before this treatment becomes widely available.
What are the potential benefits of this therapy? Potential benefits include improved mobility, reversal of hindbrain herniation, and improved bladder and bowel function.
Did you know? Hindbrain herniation, a serious complication of spina bifida, was reversed in all six babies who participated in the CuRE trial.
Want to learn more about spina bifida and available resources? Visit Shine.
Share your thoughts! What are your hopes for the future of spina bifida treatment? Leave a comment below.
